Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.66M | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Revenue growth | — | 383.8% | -32.9% | 46.9% | 15.2% | 48.3% |
| Operating income | -$52.2M | -$58.2M | -$111M | -$114M | -$146M | -$111M |
| Operating margin | -681.8% | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Net income | -$52.0M | -$58.2M | -$108M | -$102M | -$130M | -$102M |
| Net margin | -678.8% | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
| EPS (diluted) | -$1.63 | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $70.1M | -$59.5M | -$109M | -$118M | -$132M | -$139M |
| Capital expenditures | $1.11M | $1.84M | $7.69M | $1.53M | $754K | $1.05M |
| Free cash flow | $69.0M | -$61.4M | -$117M | -$120M | -$132M | -$140M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.4M | $143M | $60.0M | $66.4M | $69.5M | $112M |
| Total assets | $207M | $500M | $436M | $403M | $316M | $399M |
| Total liabilities | $169M | $155M | $187M | $149M | $117M | $52.5M |
| Shareholders' equity | $38.6M | $345M | $249M | $253M | $200M | $346M |
| Retained earnings | -$103M | -$161M | -$270M | -$371M | -$502M | -$603M |
| Shares (wtd avg diluted) | 40.4M | 62.1M | 87.8M | 94.6M | 109M | 116M |
Every figure is extracted from Tango Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.